SCHEMBL4257547

SCHEMBL4257547

O=C(Nc1ccc(-c2nc(-c3ccccc3)c(C(F)(F)F)o2)cc1)c1ccncc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 2/20 0.69
POLB P06746 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
ALDH1A1 P00352 2/20 0.57
MAPT P10636 2/20 0.57
LMNA P02545 1/20 0.57
TSHR P16473 1/20 0.57
MAPK1 P28482 1/20 0.57
DGAT1 O75907 5/20 0.54
STAT3 P40763 1/20 0.53
TRPV1 Q8NER1 5/20 0.52
KDM4E B2RXH2 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
HTT P42858 1/20 0.51
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
HDAC4 P56524 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
JAK2 O60674 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4261440 0.93 SMO (0.74) SMODGAT1TRPV1NPC1RAB9A
SCHEMBL4254381 0.89 SMO (0.69) SMOPOLBSMN1; SMN2MAPTLMNA
SCHEMBL4260410 0.88 SMO (0.68) SMOSMN1; SMN2MAPTLMNADGAT1
SCHEMBL4263809 0.88 SMO (0.74) SMOSMN1; SMN2MAPTLMNADGAT1
SCHEMBL4252955 0.85 SMO (0.64) SMODGAT1TRPV1RXFP1HTT
SCHEMBL4262412 0.85 SMO (0.64) SMOPOLBSMN1; SMN2ALDH1A1MAPT
SCHEMBL4263832 0.85 SMO (0.64) SMOPOLBSMN1; SMN2MAPTDGAT1
SCHEMBL4259931 0.85 SMO (0.64) SMOMAPTDGAT1TRPV1HDAC6
SCHEMBL4256983 0.85 SMO (0.63) SMOPOLBMAPTDGAT1TRPV1
SCHEMBL4259960 0.84 SMO (0.66) SMOPOLBSMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US claimed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US claimed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO claimed
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US disclosed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US disclosed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE OXA1L, CYP11B2, CYP3A7 SMO 1063/4885POLB 1497/4885SMN1; SMN2 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.